Diamond Phase III

The Diamond Light Source, a synchrotron the size of a football stadium, is adding ten new experimental stations—called beamlines—to its arsenal, bringing the total to 32. This matters because a synchrotron acts like a super-powered microscope, firing intense beams of light—from infrared to hard X-rays—to reveal the atomic and molecular structure of almost anything. The UK’s existing beamlines are oversubscribed, particularly for structural biology and pharmaceutical drug design. The new beamlines will specifically address this bottleneck: at least six will be dedicated to macromolecular crystallography, the technique used to map the 3D shapes of proteins and other biological molecules. Another suite of imaging beamlines will cover life sciences, from cells to tissues, while others probe electronic structure in materials. If this succeeds, the impact will be felt across industries that rarely make headlines. Pharmaceutical companies will get faster, automated access to the data needed to design new drugs. Engineers and materials scientists will study battery components or catalysts at atomic resolution. Even cultural heritage researchers will use the beams to analyse ancient artefacts without damaging them. The expansion is designed to keep the UK competitive in fundamental science and industrial R&D, quietly underpinning everything from medicine to manufacturing.